Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
127,940,509
-
Total 13F shares
-
34,351,929
-
Share change
-
+34,351,929
-
Total reported value
-
$744,420,532
-
Price per share
-
$21.41
-
Number of holders
-
53
-
Value change
-
+$744,420,530
-
Number of buys
-
53
Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q3 2021
As of 30 Sep 2021,
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) was held by
53 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,351,929 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., HHLR ADVISORS, LTD., FMR LLC, FIL Ltd, Miura Global Management, LLC, ORBIMED ADVISORS LLC, BlackRock Inc., VANGUARD GROUP INC, Octagon Capital Advisors LP, and PURA VIDA INVESTMENTS, LLC.
This page lists
53
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.